Updated: March 7, 2024
10:10-10:25 | Bayer Industry Sponsored Speakers' Corner | EXHIBITION AREA |
Experience sustained disease control (SDC) with aflibercept 8mg in nAMD and DME Kenneth Fan, USA; Peter Kaiser, USA; John Kitchens, USA | ||
12:15–13:15 | Bayer Industry Sponsored Luncheon Symposium: A turning point in retinal care (Lunch boxes served 12:00–12:15) | HALL A |
Chair: | Anat Loewenstein, Israel | |
12:15-12:20 | Welcome and introductions Anat Loewenstein, Israel | |
12:20-12:28 | Aflibercept’s unique MoA: rationale for a higher molar dose Peter Kaiser, USA | |
12:28-12:40 | A turning point in patient care: aflibercept 8mg in nAMD John Kitchens, USA | |
12:40-12:52 | A turning point in patient care: aflibercept 8mg in DME Sobha Sivaprasad, UK | |
12:52-13:12 | Navigating a diverse patient landscape: experience so far Moderator: Anat Loewenstein, Israel Panelists/presenters: Kenneth Fan, USA; Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK | |
13:12-13:15 | Summary and close Anat Loewenstein, Israel | |
13:25-13:40 | Bayer Industry Sponsored Speakers' Corner | EXHIBITION AREA |
‘A Chat with Anat’: Are we entering a new era for patients and clinicians? Anat Loewenstein, Israel; Tariq Aslam, UK | ||
SATURDAY MARCH 16, 2024 | ||
10:10-10:25 | Bayer Industry Sponsored Speakers' Corner | EXHBITION AREA |
A turning point in nAMD: incorporating aflibercept 8mg into clinical practice Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK | ||
12:15–13:15 | Evolve Industry Sponsored Luncheon Symposium: Geographic Atrophy in the Age of Approved Therapy: Diagnosis, Clinical Trial Data, and Real-World Treatment Approaches Supported by an educational grant from Astellas (Lunch boxes served 12:00-12:15) | HALL A |
Panelists: | Anat Loewenstein, Israel; Baruch Kuppermann, USA; Jordi Monés, Spain | |
Diagnosis of GA in clinical settings | ||
Prognosticating progression | ||
Trial data for approved drugs | ||
. | Real-world treatment decisions | |
Cases | ||
13:30-14:30 | Abbvie Industry Sponsored Dessert Symposium: The importance of inflammation and biomarkers in DME: a debate (Dessert boxes served 13:15 -13:30) | HALL A |
Chairs: | Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
13:30-13:35 | Welcome and introductions Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
13:35-13:50 | Role of Inflammation in DME Miltiadis Tsilimbaris, Greece | |
13:50-14:09 | Debate 1: Imaging biomarkers can reliably indicate inflammation in DME | |
13:50-13:57 | For: Irini Chatziralli, UK | |
13:57-14:04 | Against: Miltiadis Tsilimbaris, Greece | |
14:04-14:09 | Discussion and Q&A | |
14:09-14:28 | Debate 2: Early resolution of intraretinal fluid in DME is more likely to be achieved with steroid than with anti-VEGF | |
14:09-14:16 | For: Anat Loewenstein, Israel | |
14:16-14:23 | Against: Sobha Sivaprasad, UK | |
14:23-14:28 | Discussion and Q&A | |
14:28-14:30 | Close Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
14:40-14:55 | Bayer Industry Sponsored Speakers' Corner | EXHIBITION AREA |
A turning point in DME: implementing aflibercept 8mg in the clinic Peter Kaiser, USA; John Kitchens, USA; Sobha Sivaprasad, UK |